Preconfigured applications: DRAGEN v4.4 will offer "push-button" analysis for oncology workflows, including the first and ...

Emergen Research Logo Driven by Advances in Gene Sequencing and Growing Need for Precision MedicineVANCOUVER, BRITISH COLUMBIA, CA ...

Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles. Read how ILMN ...

DRAGEN v4.4 enhancements will simplify NGS a Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2025.

It's been a good week for Illumina, Inc. (NASDAQ:ILMN) shareholders, because the company has just released its latest first-quarter results, and the shares gained 4.3% to US$81.57. Revenues were ...

More than a decade ago, researchers launched the BabySeq Project, a pilot program to return newborn genomic sequencing results to parents and measure the effects on newborn care.

In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

Epigenetics research in Japan is poised for significant growth, driven by advances in biotechnology and a growing emphasis on personalized medicine. As the rest of the world leans towards more ...

As reported at AGBT, the dominant second-generation sequencing platforms—HiSeq from Illumina (San Diego ... to keep pace with the sequencing machines. Perhaps the greatest impact, though ...

'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...